Showing results (281-290 of 415) with videos related to

Sort By:
Pageof 42
The Journal of Biological Chemistry|October 23, 2015
Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in OsteoblastsKimberly N Kremer, Amel Dudakovic, Allan D Hess, et al.
AIDS (London, England)|June 1, 1989
Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual menM T Schechter, K J Craib, T N Le, et al.
Hematological Oncology|January 19, 2022
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapyDeanna Brackman, Doerthe Eckert, Rajeev Menon, et al.
Leukemia & Lymphoma|July 21, 2021
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Jonathan A Webster, Meera Yogarajah, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionAmy E DeZern, Anthony Sung, Sharon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.
Epigenetics|July 31, 2010
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemiaElizabeth A Griffiths, Steven D Gore, Craig M Hooker, et al.
Blood|January 27, 2005
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasiaDamiano Rondelli, Giovanni Barosi, Andrea Bacigalupo, et al.
Frontiers in Oncology|November 16, 2020
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AMLAlexander J Ambinder, Kelly Norsworthy, Daniela Hernandez, et al.
The Science of the Total Environment|May 11, 2023
PFAS contaminated asphalt and concrete - Knowledge gaps for future research and managementG B Douglas, J L Vanderzalm, M Williams, et al.
Pageof 42